GFAP and Alzheimer disease: In AD, amyloid plaque deposition increased in an APPswe/PS1ΔE9 transgenic mouse model when astrocyte reactivity was reduced through glial fibrillary acid protein (GFAP)/Vimentin double knockout [36].